• Cellvizio®
    • Overview
    • Education
    • Economics
  • Indications
    • Gastroenterology
      • Barrett’s Esophagus
      • Pancreatic Cysts
      • Gastric Disease
      • Inflammatory Bowel Diseases
      • Irritable Bowel Syndrome – Food Intolerance
      • Bilio-Pancreatic Strictures
      • Colorectal Lesions
    • Pulmonology
      • Lung Nodules
      • Lung Transplant
    • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

by Elizabeth | Jul 28, 2026 | News

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio  AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%  Paris and Boston, July 28,...
Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 

by Elizabeth | Jul 21, 2026 | News

 H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1  CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion  Strong systems pipeline for H2 2026 in the U.S. and new international...
Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

by Elizabeth | Jul 16, 2026 | News

Paris and Boston, July 16, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its...
Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

by Elizabeth | Jul 15, 2026 | News

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing with an existing shareholder intended to secure the Company’s path...
Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

by Elizabeth | Jun 4, 2026 | News, News

All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th Paris and Boston, June 4, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and...
« Older Entries

Articles récents

  • Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 
  • Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth 
  • Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity
  • Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth
  • Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}